Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics Q3 EPS $(0.30) Beats $(0.82) Estimate, Sales $9.984M Beat $4.840M Estimate
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
Xilio Therapeutics Doses First Participant In Its Phase 1/2 Clinical Study Of XTX501 To Treat Metastatic Non-Small Cell Lung Cancer
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics Q2 EPS $(0.33) Beats $(0.59) Estimate, Sales $18.692M Beat $12.720M Estimate
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Xilio Therapeutics Q1 EPS $(0.58) Beats $(0.66) Estimate, Sales $12.648M Beat $8.520M Estimate
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Xilio's XTX601 Shows Tumor-Selective Activation And Strong Preclinical Anti-Tumor Activity With Favorable Safety Profile At AACR 2026
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Xilio Therapeutics Q4 EPS $0.81 Beats $(0.12) Estimate, Sales $13.686M Beat $7.960M Estimate
Xilio Therapeutics Announces XTX501 Shows Robust Monotherapy Activity; Plans IND Submission In Middle Of 2026; Intends To Start Phase 1 Study Of XTX501 In H2 This Year
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.